Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Is Cigna Group the Nation's Best-Run Health Insurance Company?: https://www.marketbeat.com/logos/articles/med_20240525153829_chart-ci.jpg
Is Cigna Group the Nation's Best-Run Health Insurance Company?

Health insurance companies in the medical sector have not fared well in 2024. Medicare Advantage (MA) plans were a bountiful source of income until the second half of 2023. Humana Inc. (NYSE: HUM)

Medtronic Dips: Is Now the Time to Buy?: https://www.marketbeat.com/logos/articles/med_20240523121523_chart-mdt-5232024ver001.png
Medtronic Dips: Is Now the Time to Buy?

Shares of Medtronic (NYSE: MDT) are falling following its FQ4 release and guidance, opening up a potential buying opportunity. The question is whether its value, yield, balance sheet and cash flow

CVS Health Stock Has a Silver Lining Called Value: https://www.marketbeat.com/logos/articles/med_20240519153028_chartzy-cvs.jpg
CVS Health Stock Has a Silver Lining Called Value

Integrated healthcare retailer and insurer CVS Health Co. (NYSE: CVS) stock presents a value not seen in years. The medical sector giant saw its shares punished on its Q1 2024 top and bottom line

Will the Biotech Sector Shift From Lagger to Leader?: https://www.marketbeat.com/logos/articles/med_20240509132613_will-the-biotech-sector-shift-from-lagger-to-leade.jpg
Will the Biotech Sector Shift From Lagger to Leader?

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the

AbbVie Tracking for New Highs in 2024: https://www.marketbeat.com/logos/articles/med_20240507101742_chart-abbv-572024.png
AbbVie Tracking for New Highs in 2024

Shares of AbbVie (NYSE: ABBV) fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira

Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report: https://www.marketbeat.com/logos/articles/med_20240505135039_chartszy-pfe.jpg
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report

Biopharma giant Pfizer Inc. (NYSE: PFE) has given back all its COVID gains and more. Shareholders have sat through a painful two-year selloff from the stock's $61.71 high on December 20, 2021, to

Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher: https://www.marketbeat.com/logos/articles/med_20240430080639_analyst-sentiment-revenue-growth-will-lead-abbvie.jpg
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher

AbbVie Inc. (NYSE: ABBV) stock is recovering after falling over 4% in the week preceding its earnings report on April 26, 2024. As the market closed on Monday, April 29, ABBV stock posted a gain

Abbott Laboratories Outlook is Healthy: Buy the Dip: https://www.marketbeat.com/logos/articles/med_20240417090953_chart-abt-4172024ver001.png
Abbott Laboratories Outlook is Healthy: Buy the Dip

Abbott Laboratories' (NYSE: ABT) share price was corrected at the end of CQ1 2024 on growth, profitability and capital returns concerns. The FQ1 results, however, belie the fear and have the market

Undervalued UnitedHealth Group Won’t Be For Long: https://www.marketbeat.com/logos/articles/med_20240416091545_chart-unh-4162024ver001.png
Undervalued UnitedHealth Group Won’t Be For Long

UnitedHealth Group's (NYSE: UNH) Q1 results were better than expected for two reasons: First, the stock price is now rebounding from long-term lows and deep value territory with ample upside

Biotech Sector Nears Breakout: Will it Outperform in Q2?: https://www.marketbeat.com/logos/articles/med_20240401185946_biotech-sector-nears-breakout-will-it-outperform-i.jpg
Biotech Sector Nears Breakout: Will it Outperform in Q2?

The popular iShares Biotechnology ETF (NASDAQ: IBB) has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout. 

The bullish

DexCom Stock Gains from GLP-1 Diabetic Users: https://www.marketbeat.com/logos/articles/med_20240331131923_chart-dxcm.jpg
DexCom Stock Gains from GLP-1 Diabetic Users

DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People with diabetes use CGM systems to

7 Stocks That Will Drive the Weight Loss Drugs Market: https://www.marketbeat.com/logos/articles/med_20240327132929_7-stocks-that-will-drive-the-weight-loss-drugs-mar.jpg
7 Stocks That Will Drive the Weight Loss Drugs Market

The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems.  Pharmaceutical companies are

4 Oversold Large Cap Stocks Yielding High Dividends: https://www.marketbeat.com/logos/articles/med_20240313190843_4-oversold-large-cap-stocks-yielding-high-dividend.jpg
4 Oversold Large Cap Stocks Yielding High Dividends

As the market continues its relentless ascent to new heights, propelled by the surging tech sector and hype surrounding AI,  the murmurs of potential interest rate cuts by the Federal Reserve

Eilt: Völlig neue Krebsbehandlung - Hautkrebs vollständig geheilt. Diesen Biotech Hot Stock jetzt kaufen nach 9.290% mit Novo-Nordisk ($NVO): https://www.irw-press.at/prcom/images/messages/2024/73926/AC_Vidac_130324.001.png
Eilt: Völlig neue Krebsbehandlung - Hautkrebs vollständig geheilt. Diesen Biotech Hot Stock jetzt kaufen nach 9.290% mit Novo-Nordisk ($NVO)

Eilt: Völlig neue Krebsbehandlung - Hautkrebs vollständig geheilt. Diesen Biotech Hot Stock jetzt kaufen nach 9.290%

 

13.03.24 08:02

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Eilt: Studie für völlig neue Krebsbehandlung genehmigt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX): https://www.irw-press.at/prcom/images/messages/2024/73909/aktiencheck120324.001.png
Eilt: Studie für völlig neue Krebsbehandlung genehmigt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX)

Eilt: Studie für völlig neue Krebsbehandlung genehmigt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX)

 

12.03.24

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Link

Medtronic is a Dividend Aristocrat That Keeps Gaining: https://www.marketbeat.com/logos/articles/med_20240310135440_charts-mdt.jpg
Medtronic is a Dividend Aristocrat That Keeps Gaining

Medical device maker Medtronic PLC (NYSE: MDT) is a Dividend Aristocrat in the medical and healthcare sectors. The medical device maker has raised its dividend payout for 46 consecutive years

Sensationelle Studienergebnisse - Hautkrebs vollständig geheilt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). : https://www.irw-press.at/prcom/images/messages/2024/73886/AC-03-11-24_AC01.001.png
Sensationelle Studienergebnisse - Hautkrebs vollständig geheilt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB).

Sensationelle Studienergebnisse - Hautkrebs vollständig geheilt. 797% Biotech Hot Stock nach 10.996% mit Pfizer ($PFE)

 

11.03.24 08:02

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Eilt: Hautkrebs vollständig geheilt - Blockbuster gegen Hautkrebs. Neuer 797% Biotech Aktientip nach 15.973% mit BioNTech ($BNTX): https://www.irw-press.at/prcom/images/messages/2024/73877/AC-080324.001.png
Eilt: Hautkrebs vollständig geheilt - Blockbuster gegen Hautkrebs. Neuer 797% Biotech Aktientip nach 15.973% mit BioNTech ($BNTX)

Eilt: Hautkrebs vollständig geheilt - Blockbuster gegen Hautkrebs. Neuer 797% Biotech Aktientip nach 15973% mit BioNTech

 

08.03.24 08:03

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

Eilt: Durchbruch in der Krebsforschung - Hautkrebs vollständig geheilt. 661% Biotech Hot Stock nach 15.973% mit Biotech ($BNTX): https://www.irw-press.at/prcom/images/messages/2024/73865/AC-070324.001.png
Eilt: Durchbruch in der Krebsforschung - Hautkrebs vollständig geheilt. 661% Biotech Hot Stock nach 15.973% mit Biotech ($BNTX)

Eilt: Durchbruch in der Krebsforschung - Hautkrebs vollständig geheilt. 661% Biotech Hot Stock nach 134.452% mit Biogen

 

07.03.24 08:02

AC Research

 

London (www.aktiencheck.de , Anzeige)

 

Biotech Hot Stock 2024: Erstklassige Studienergebnisse - Hautkrebs vollständig geheilt. Diese Biotech-Aktie jetzt kaufen nach 15.973% mit Biotech ($BNTX): https://www.irw-press.at/prcom/images/messages/2024/73854/AC_Vidac_060324.001.png
Biotech Hot Stock 2024: Erstklassige Studienergebnisse - Hautkrebs vollständig geheilt. Diese Biotech-Aktie jetzt kaufen nach 15.973% mit Biotech ($BNTX)

Biotech Hot Stock 2024: Erstklassige Studienergebnisse - Hautkrebs vollständig geheilt. Diese Biotech-Aktie jetzt kaufen

 

06.03.24 08:02

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

Is UnitedHealth Group Stock a Strong Buy or a Falling Knife?: https://www.marketbeat.com/logos/articles/med_20240304134833_is-unitedhealth-group-stock-a-strong-buy-or-a-fall.jpg
Is UnitedHealth Group Stock a Strong Buy or a Falling Knife?

UnitedHealth Group Inc. (NYSE: UNH) has given up almost all of its 12-month gains in the last week after two unrelated incidents have rocked the company. At the close of trading on March 1, 2024

Eilt: 95% weniger Medikamente - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73839/acresearch050324.001.png
Eilt: 95% weniger Medikamente - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: 95% weniger Medikamente - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Hot Stock nach 9.290% mit Novo-Nordisk

 

05.03.24

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Eilt: 100 mal wirksamer gegen Krebs - Großinvestoren unmittelbar vor Einstieg. Neuer 503% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73815/AC-040324.001.png
Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73797/AC-010324.001.png
Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. 503% Biotech Aktientip nach 134.452% mit Biogen

 

01.03.24 08:03

AC Research

 

London (www.aktiencheck.de, Anzeige)